Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SYK vs EW: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SYK Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 5–5 Matrix Metrics)

SYK Overall Winner 6-Pillar Tally: SYK 3 – 3 EW Matrix Metrics: SYK 5 – 5 EW

As of Nov 16, 2026, Stryker Corporation (SYK) is the stronger overall head-to-head candidate over Edwards Lifesciences Corp (EW) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Options & Positioning, R&D & Supply-Chain Moat). SYK carries a Unified Composite Score of 46.5/100 (HOLD) at $310.79 (19.0x Forward P/E, 24.0% operating margin), whereas EW carries 31.5/100 (SELL) at $106.66 (31.6x Forward P/E, 28.8% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SYK vs EW
SYK NYSE Head-to-Head Winner
Stryker Corporation
Surgical & Medical Instruments & Apparatus
$310.79
+0.37% 1D
Market Cap $118.9B
TTM Revenue $26.3B
Forward P/E 19.0x
Beta / 30D Vol 0.22β · 50% Vol
Unified Composite Score
46.5 / 100 HOLD
Tech 37.0 Fund 49.0 Flow 58.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.5 · SMA20: $312.55 · SMA50: $292.40
EW NYSE
Edwards Lifesciences Corp
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$106.66
-0.46% 1D
Market Cap $60.8B
TTM Revenue $6.67B
Forward P/E 31.6x
Beta / 30D Vol 0.44β · 24% Vol
Unified Composite Score
31.5 / 100 SELL
Tech 50.0 Fund 29.0 Flow 51.0 Mom 44.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.7% over 20 days), RSI 79
RSI-14: 79.4 · SMA20: $97.03 · SMA50: $90.77

6-Pillar Scorecard Institutional Category Breakdown (SYK 3 – 3 EW)

Columns: Metric · SYK · EW
1. Valuation Multiples SYK
Forward P/E 19.0x 31.6x
Trailing P/E 33.3x 61.5x
PEG Ratio 1.54x 2.33x
EV / Revenue 5.0x 8.8x
2. Growth & Scale EW
Revenue Growth (YoY) +7.6% +10.5%
Earnings Growth (YoY) -11.7% +6.7%
TTM Revenue (USD) $26.3B $6.67B
Market Cap $118.9B $60.8B
3. Profitability & Quality EW
Gross Margin 65.7% 78.0%
Operating Margin 24.0% 28.8%
Net Profit Margin 13.8% 15.3%
Return on Equity (ROE) 16.0% 9.3%
4. Balance Sheet & Cash Flow EW
Cash Generation (TTM) $4.57B $1.42B
Cash Flow Margin 17.4% 21.3%
Net Cash / Leverage $11.7B Net Debt (0.64x D/E) $2.41B Net Cash
Dividend Yield 1.10% None (0.00%)
5. Options & Positioning SYK
Options Structure Phase SURGE UNCLASSIFIED
Current IV / %ile 28.1% (5th %ile) 24.6% (34th %ile)
Put/Call OI Skew 0.30x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat SYK
OpEx & R&D Intensity 41.7% of Rev ($11.0B) 49.2% of Rev ($3.28B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Concentrated Oligopoly Moat Scale & Operating Efficiency Moat
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SYK (5) vs EW (5)
Institutional Metric SYK EW Criterion Row Edge
Market Capitalization
Scale
$118.9B $60.8B Larger Scale SYK
Trailing P/E Ratio
Valuation
33.3x 61.5x Lower Multiple SYK
Forward P/E Ratio
Valuation
19.0x 31.6x Lower Multiple SYK
Revenue Growth (YoY)
Growth
+7.6% +10.5% Higher Growth EW
Operating Margin (TTM)
Profitability
24.0% 28.8% Higher Margin EW
Net Profit Margin
Profitability
13.8% 15.3% Higher Margin EW
Return on Equity (ROE)
Capital Efficiency
16.0% 9.3% Higher ROE SYK
52-Week Range Position
Momentum
36% ($267–$389) 96% ($75–$108) Stronger Trend EW
Beta / 30D Volatility
Risk Regime
0.22β · 50% Vol 0.44β · 24% Vol Lower Realized Risk EW
Unified Institutional Score
Composite Signal
46.5 / 100 (HOLD) 31.5 / 100 (SELL) Higher Composite SYK
Trailing 12M Revenue (USD)
Operating Scale
$26.3B $6.67B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
65.7% 78.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.54x PEG · 5.0x EV/Rev 2.33x PEG · 8.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$4.57B ($11.7B Net Debt (0.64x D/E)) $1.42B ($2.41B Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EW +17.69 pp
SYK: +5.47% · EW: +23.16%
3M Horizon EW +23.44 pp
SYK: -6.21% · EW: +17.23%
6M Horizon EW +30.23 pp
SYK: -0.78% · EW: +29.45%
1Y Horizon EW +40.63 pp
SYK: -16.77% · EW: +23.86%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SYK Revenue EW Revenue SYK Op. Margin EW Op. Margin Margin Leader
FY2018 $13.6B $3.72B 18.7% 20.1% EW
FY2019 $14.9B $4.35B 18.2% 26.4% EW
FY2020 $14.3B $4.39B 15.5% 20.5% EW
FY2021 $17.1B $5.23B 15.1% 32.3% EW
FY2022 $18.4B $4.46B 15.4% 33.6% EW
FY2023 $20.5B $5.01B 19.0% 26.1% EW
FY2024 $22.6B $5.44B 16.3% 25.3% EW
FY2025 $25.1B $6.07B 19.5% 20.8% EW

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SYK SURGE
8d in phase · OBV DISTRIBUTION
Current IV 28.1%
IV Percentile 5th %ile
Put/Call OI Skew 0.30x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact SYK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EW UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 24.6%
IV Percentile 34th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EW Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SYK Moat Profile Concentrated Oligopoly Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $118.9B market capitalization and 24.0% operating margin.
OpEx & R&D Reinvestment 41.7% of Rev ($11.0B)
90D Engineering Disclosures 0 Published · Surgical Robotics
EW Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $60.8B market capitalization and 28.8% operating margin.
OpEx & R&D Reinvestment 49.2% of Rev ($3.28B)
90D Engineering Disclosures 0 Published

Investor FAQ SYK vs EW Key Questions & Quantitative Answers

As of Nov 16, 2026, Stryker Corporation (SYK) is the stronger overall head-to-head candidate over Edwards Lifesciences Corp (EW) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Options & Positioning, R&D & Supply-Chain Moat). SYK carries a Unified Composite Score of 46.5/100 (HOLD) at $310.79 (19.0x Forward P/E, 24.0% operating margin), whereas EW carries 31.5/100 (SELL) at $106.66 (31.6x Forward P/E, 28.8% operating margin). Technically, SYK sits in a Neutral phase (RSI 51.5, SURGE options structure) and EW sits in a Markup phase (RSI 79.4, UNCLASSIFIED options structure).

EW leads the Growth & Scale pillar: SYK posts +7.6% YoY revenue growth and -11.7% YoY earnings growth on $26.3B TTM revenue (65.7% gross margin, 24.0% operating margin), compared with EW at +10.5% YoY revenue growth and +6.7% YoY earnings growth on $6.67B TTM revenue (78.0% gross margin, 28.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SYK cumulative revenue shifted +84.7% while EW shifted +63.2%. In operating R&D and SG&A reinvestment, SYK deploys 41.7% of Rev ($11.0B) (0 90-day corporate R&D disclosures) versus 49.2% of Rev ($3.28B) (0 disclosures) for EW.

SYK screens cheaper on headline valuation multiples. SYK trades at 19.0x Forward P/E, 33.3x Trailing P/E, 1.54x PEG, and 5.0x EV/Revenue (17.4% FCF margin), whereas EW trades at 31.6x Forward P/E, 61.5x Trailing P/E, 2.33x PEG, and 8.8x EV/Revenue (21.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SYK (16.0% ROE) versus EW (9.3% ROE) capital efficiency.

In options market volatility and institutional positioning, SYK carries 28.1% implied volatility (5th %ile, Compressed (<25th %ile)), a 0.30x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.22β · 50% Vol realized risk). By comparison, EW carries 24.6% implied volatility (34th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.44β · 24% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.